4.4 Article

Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells

Journal

PATHOLOGY & ONCOLOGY RESEARCH
Volume 25, Issue 3, Pages 1233-1243

Publisher

FRONTIERS MEDIA SA
DOI: 10.1007/s12253-019-00610-7

Keywords

Breast cancer; Insulin resistance; TIM3; PD1

Funding

  1. Consejo Nacional de Ciencia y Tecnologia [FOSISS-233471, SEP-134341]
  2. [NHI-R01A1119131]

Ask authors/readers for more resources

Epidemiological evidence points to a link between insulin resistance (IR) and breast cancer (BrCA). Insulin plays a role in CD8+ T cells (CD8T) differentiation and function and affects adipocytokines levels. CD8T activity in BrCA is associated with favorable outcome; while PD1 and TIM3 are markers of CD8T exhaustion and play critical roles in the negative regulation of T cell responses. Patients with (BrCA) have high expression levels of PD1 on circulating. Therefore, we hypothesized that BrCA and IR could affect PD1 and/or TIM3 expression on circulating CD8T. We determine PD1 and TIM3 expression on CD8T and analyze the relationship of CD8T phenotype with serum insulin and plasma adipocytokines levels in the different groups. We enrolled four groups of treatment-naive patients: women without neoplasms (Neo-)/without IR (IR-), Neo-/with IR (IR+), BrCa/IR- and BrCa/IR+. We found interactions between BrCA and IR with respect to TIM3 on naive and central memory (CM) CD8T subsets. Furthermore, BrCA had a greater PD1+TIM3- CD8T frequency in CD8T subsets than Neo-. IR+ presented a significantly lower PD1+TIM3- frequency in CD8T subsets compare to Non-IR. In addition, we found a negative correlation between insulin levels, HOMA and frequency of PD1+TIM3- in CD8T and a positive correlation between adiponectin levels and the frequency PD1+TIM3- in CD8T. The increased expression of PD1 on different subsets of CD8T from BrCa patients is consistent with immunological tolerance, whereas IR has a contrary effect. IR could have a deleterious role in the activation of CD8T that can be relevant to new BrCa immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available